Communique from the Annual General Meeting in 2cureX AB (publ)

May 28 | 2020
Today, on May 28th, 2020, the Annual General Meeting (“AGM”) was held in 2cureX AB (publ). Below follows a summary of the resolutions. The resolutions were passed with the required majority.

Disposition of the company’s profit or loss
The AGM resolved to dispose of the company’s results according to the Board’s proposal in the annual report. The AGM also resolved that no dividend be paid for the financial year 2019. In addition, the AGM resolved to grant discharge from liability to the members of the Board and the CEO for the financial year 2019.

Determination of the number of Board members, Board deputies and the number of auditors and auditor deputies and determination of fees for the Board and the auditors.
The AGM resolved that the Board of Directors shall consist of five board members and no deputy board member, and that board fees shall be SEK 200,000 to the chairman of the board and with SEK 100,000 each to other board members excluding Timm Jessen and Ole Thastrup. Furthermore, the AGM resolved that one auditor and no deputy auditor shall be appointed and that auditors’ fees shall be paid according to approved invoice in accordance with customary charging standards.

Election of Board and auditor
The AGM resolved to re-elect Povl-André Bentz, Camilla Huse Bondesson, Jørgen Drejer, Timm Jessen and Ole Thastrup as board members. Povl-André Bentz was re-elected as Chairman of the Board. Furthermore, the AGM resolved that the company’s auditor Öhrlings PricewaterhouseCoopers AB was re-elected until the end of the Annual General Meeting, which will be held next financial year.

The Board, or other by the Board appointed, was authorized to decide on minor corrections required for registration with the Swedish Companies Registration Office.

For more information about 2cureX:

Ole Thastrup, Chief Executive Officer
Telephone: +45 2211 5399

Certified Adviser

Svensk Kapitalmarknadsgranskning AB
Phone: +46 11 32 30 732


About 2cureX

2cureX has developed the IndiTreat® (Individual Treatment) test. IndiTreat® establishes thousands of 3D micro-tumors that are similar to the patient’s tumor and identifies the treatment that most effectively kills the patient’s tumor. Immediately after the test, the patient can be offered the selected treatment.

IndiTreat® is being clinically validated in clinical studies in colorectal cancer, ovarian cancer, pancreatic cancer and preventive cancer medicine. The clinical programs are conducted at major cancer hospitals in Denmark, Germany and United Kingdom.

IndiTreat® is presently being introduced into the European market through an Early Access Program.

The aspiration is that IndiTreat® becomes a standard tool in Precision Medicine for cancer patients.

The company is listed at the Nasdaq First North Growth Market in Stockholm (symbol “2CUREX”).